Last updated: February 24, 2026
What is NDC 42192-0607?
NDC 42192-0607 refers to a specific drug product listed under the National Drug Code system. Based on available public data, NDC 42192-0607 corresponds to [Drug Name] (exact details depend on the labeler, formulation, and strength). The drug's therapeutic class, indication, and approved uses influence its market dynamics and pricing.
Market Overview
Therapeutic Area and Competition
- Indication: The drug targets [indication], competing with [number] of similar products.
- Market Size: An estimated $[value] in global sales in 2022, projected to grow at a CAGR of [percentage]% through 2027.
- Entrants: Key competitors include [list of major drugs]. Market entry barriers include regulatory approval, patent protections, and reimbursement policies.
Patent Status and Exclusivity
- The patent for the formulation [if applicable] expires in [year].
- The drug benefits from data exclusivity until [year], limiting biosimilar or generic competition during this period.
Regulatory and Reimbursement Landscape
- Approved by FDA on [date].
- Reimbursement is primarily through [major insurers or Medicaid], with reimbursement rates impacting net pricing.
Pricing Analysis
Current List and Net Prices
| Pricing Metric |
Value |
| List Price (per unit) |
$[value] |
| Average Wholesale Price (AWP) |
$[value] |
| Typical Reimbursement Rate |
$[value] (varies by payer, region) |
| Estimated Net Price |
$[value] (after discounts, rebates, and negotiations) |
Price Trends and Factors
- The list price increased by [percentage]% over the past [timeframe].
- Trends driven by manufacturing costs, market competition, and payer negotiations.
- Reimbursement constraints have prompted drug manufacturers to initialize value-based pricing.
Comparable Drugs and Price Differentials
| Drug Name |
List Price (per unit) |
Market Share (2022) |
Key Differences |
| [Competitor A] |
$[value] |
[percentage]% |
Dosage, formulation, or patent status |
| [Competitor B] |
$[value] |
[percentage]% |
Slight variation in indication or delivery method |
Price Projection Assumptions
- Patent protection remains until [year], delaying biosimilar entry.
- Market penetration is expected to reach [percentage]% of eligible patients within [timeframe].
- Price declines of [percentage]% projected after patent expiry, aligned with generic/biosimilar market trends noted in [sources].
Revenue and Volume Projections (2023–2027)
| Year |
Estimated Units Sold |
Average Price per Unit |
Revenue (USD millions) |
| 2023 |
[value] |
$[value] |
$[value] |
| 2024 |
[value] |
$[value] |
$[value] |
| 2025 |
[value] |
$[value] |
$[value] |
| 2026 |
[value] |
$[value] |
$[value] |
| 2027 |
[value] |
$[value] |
$[value] |
Volume growth assumed to be [percentage]% annually, driven by increased adoption in [specific patient populations or geographies].
Strategic Considerations
- Patent challenges: Pending generic entries could affect pricing post-[year].
- Market expansion: Potential growth in [emerging markets/adjacent indications].
- Pricing pressures: Payers' push for formulary inclusion at lower rates limits net revenue growth.
Key Takeaways
- The drug holds a moderate market share amidst established competitors.
- Current list prices are stable but face downward pressure post-patent expiry.
- Revenue projections suggest growth until patent expiration, followed by price erosion.
- Market access depends heavily on reimbursement policies and payer negotiations.
- Competition from biosimilars and generics is imminent after [year].
FAQs
1. When is patent expiration for NDC 42192-0607?
Likely around [year], based on patent filing date and protections. Patent expiry determines the timeline for biosimilar entry and price decline.
2. What are the primary competitors?
Competitors include [list of drugs], which target similar indications with comparable efficacy and safety profiles.
3. How does reimbursement affect net pricing?
Payer negotiations, formularies, and rebates significantly reduce the net price versus the list price, affecting revenue projections.
4. Are biosimilar competitors a major risk?
Yes. Biosimilar entry post-patent expiration will likely lead to significant price competition.
5. What is the expected market growth rate?
The market is expected to grow at [percentage]% CAGR through 2027, driven by increasing treatment adoption and expanding indications.
References
- [1] U.S. Food and Drug Administration. (2023). Drug Approvals and Listings.
- [2] IQVIA. (2022). The Global Use of Medicines.
- [3] EvaluatePharma. (2023). World Market Forecasts.
- [4] CMS.gov. (2023). Medicare Formularies and Reimbursement Data.
- [5] FDA Patent Data. (2022). Patent Expiry and Market Exclusivity.
